MedTrace Logo

Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma

NCT01105702 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2016-08-04

Study results available
· View outcomes & findings →

Summary

This pilot phase II trial studies how well giving temozolomide, bevacizumab, lithium carbonate, and radiation therapy works in treating patients with newly diagnosed high grade glioma.

Conditions

Interventions

DRUG

Temozolomide

DRUG

Bevacizumab

DRUG

Lithium Carbonate

RADIATION

Radiation

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Atlantic Health System

    collaborator OTHER

  • NYU Langone Health

    lead OTHER

Principal Investigators

  • Deborah Gruber, MD · New York University Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2014-04-30
Completion
2015-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01105702 on ClinicalTrials.gov